Endostatin Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors
Status:
Completed
Trial end date:
2016-04-01
Target enrollment:
Participant gender:
Summary
1)Preliminarily evaluate the treatment effect of continuous vein injection of recombinant
human endostatin on NF2; 2)Preliminarily evaluate the safety and the patient's tolerance of
the treatment of endostatin; 3)Provide an objective basis for an enlarged randomized
double-blind trial.